Analysts' ratings for Viridian Therapeutics (NASDAQ:VRDN) over the last quarter vary from bullish to bearish, as provided by 13 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 5 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 5 | 3 | 0 | 0 | 0 |
| 2M Ago | 1 | 2 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $37.69, a high estimate of $61.00, and a low estimate of $27.00. Witnessing a positive shift, the current average has risen by 7.69% from the previous average price target of $35.00.
Deciphering Analyst Ratings: An In-Depth Analysis
The standing of Viridian Therapeutics...
Login or create a forever free account to read this news
Sign up/Log in